Cindy – 【國家衛生研究院】技轉及育成中心

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” (2022/11/18)

Latest news-English, Latest news-English, Latest news-English, 技術-EN / 2022 年 11 月 18 日 2022 年 11 月 21 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” Date: 2022.11.18 1. Title: NHRI technology, “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR901 is a humanized anti-HSP90a IgG1 derived from a murine hybridoma …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” (2022/11/18) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR22998: IsoQC inhibitor targeting CD47-SIRPa “Do not eat me” cancer immune checkpoint” (2022/11/18)

Latest news-English, 最新消息 / 2022 年 11 月 18 日 2022 年 11 月 17 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR22998: IsoQC inhibitor targeting CD47-SIRPa “Do not eat me” cancer immune checkpoint” Date: 2022.11.18 1. Title: NHRI technology, “DBPR22998: IsoQC inhibitor targeting CD47-SIRP “Do not eat me” cancer immune checkpoint” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR22998 is an …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26)

Uncategorized, 技術-EN, 技術轉移招商en文章, 產學研發-EN, 產學研發徵求夥伴en文章 / 2022 年 7 月 26 日 2022 年 7 月 26 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” Date: 2022.7.26 1. Title: NHRI technology, “DBPR807: A CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR807 is a small molecule CXCR4 antagonist. DBPR807 can significantly suppress tumor growth of hepatocellular carcinoma via reducing angiogenesis, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03)

技術轉移招商en文章, 技術轉移招商en文章, 技術轉移招商en文章, 產學研發-EN / 2022 年 1 月 3 日 2022 年 1 月 3 日

1. Title: NHRI technology, “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: Amplification or overexpression of MYC oncoproteins, master regulator of cancers, are observed in over 28% common cancer types. The Technology is a novel aurora kinase inhibitor which was …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03) Read More »

本院「應用於細胞治療之新穎癌症抗原(cancer antigen)抗體」公開徵求產學合作廠商(2021/2/25)

產學研發徵求夥伴 / 2021 年 2 月 25 日 2021 年 2 月 25 日

一、主旨：本院開發應用於細胞治療之癌症抗原(cancer antigen)抗體公開徵求產學合作廠商，進行藥物發展之可行性試驗。二、技術說明：本院生技與藥物研究所利用自有技術平台，包括抗體篩選、噬菌體展示資料庫、表面電漿共振、螢光流式細胞分選儀、抗體人源化、抗體藥物動力學改良以及抗體親和力成熟等技術，已篩選到具有高親和力的癌症抗原抗體，可以應用於細胞治療。三、廠商資格：須具備下列條件者依法登記且無違法紀錄。具有相關技術開發經驗與能力者佳。具國際合作經驗及臨床試驗經驗者佳。願意長期投入研發資金者佳。四、報名方式：符合上述資格且有意願者，請於110年3月15日前填妥「合作研發企劃書 — 壹、基本資料」(格式如附件二)之相關資料〔內含公司簡介及可闡明上述條件之資料〕，並標明廠商名稱和地址、聯絡人電話與電子郵件等資料，以郵寄正本並搭配傳真或電子郵件方式，送達國家衛生研究院技轉及育成中心謝汶娟女士，電話：(037)206-166#33209，E-mail：wenchuan@nhri.edu.tw；或梁華軒先生，電話：(037)206-166#33206，E-mail：huahsuan@nhri.edu.tw 五、其他：本院保有隨時修改及終止本公告之權利。詳細案件狀況請洽詢承辦人。附檔附件一：公告電子檔：「應用於細胞治療之新穎癌症抗原(cancer antigen)抗體」徵求產學合作廠商附件二：合作研發企劃書